Revenue
No reported data
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $121.2M | $73.1M | — |
| Operating expenses | $145.8M | $80.9M | — |
| Operating income | −$145.8M | −$80.9M | −$41,692 |
| Net income | −$134.0M | −$74.3M | −$41,692 |
| Basic EPSper diluted share | -$4.30 | -$5,756.41 | — |
| Diluted EPSper diluted share | -$4.30 | -$5,756.41 | — |